Poly cystic ovary syndrom. Polycystic ovarian syndrome
Conditions
Interventions
Intervention group: patients with polycystic ovary syndrome with high body mass index referred to Shahrekord endocrinology clinics who are treated with liraglutide drug under the brand name Victoza fr
Sponsors
Shahre-kord University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Women with polycystic ovary syndrome between the ages of 18 and 45 years, Written and oral consent is obtained from patients to participate in the study Do not have chronic physical diseases (except polycystic ovary syndrome) and mental diseases. According to the patient, there is no long-term use of drugs. Body mass index is more than 25 kg/m2.
Exclusion criteria
Exclusion criteria: Smoke. suffering from other causes of hyperandrogenism such as congenital adrenal hyperplasia, Cushing's syndrome, ovarian or adrenal tumor. Taking drugs that lead to side effects such as menstrual disorders, hirsutism or acne, or affect the profile of fat or blood sugar in the last 3 months, such as OCP, thiazides, corten, metformin, etc. be pregnant. Menopause Have a history of previous pancreatitis. Have a family history of medullary thyroid carcinoma (mtc).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting insulin. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Laboratory.;Fasting blood glucose. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Laboratory.;Menstruation. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Patient History.;Hirsutism. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Ferriman-Gallwey scoring system, observation.;Acne. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Observation.;TG,HDL,LDL. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Laboratory.;Weight. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Scale.;Hair loss. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Patient history. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFariba mansouri
Shahre-kord University of Medical Sciences
Outcome results
None listed